Fresenius said Monday, November 2, that it has signed an exclusive development agreement with WuXi Biologics giving the German healthcare group options on up to 37 biosimilar candidates over the next decade. The arrangement could expand its marketed and pipeline portfolio from 29 molecules to as many as 66, but development will depend on decisions about each candidate.
The company announcement describes a fee-for-service arrangement, with Fresenius paying WuXi Biologics for candidates it selects for development. Fresenius would retain exclusive global commercialization rights, including marketing authorizations, and the full economics of products brought to market under the agreement.
The scale is substantial, but the headline market figure is not a purchase price. Fresenius said the expanded portfolio would address more than €370 billion in sales of the original biologic medicines, measured at list prices. That figure is neither the value of the agreement nor a forecast of revenue Fresenius will earn. The announcement did not disclose a total contract value or an upfront payment.
Fresenius will choose programs based on market attractiveness, development risk and expected returns. Its research and development spending will rise as selected programs advance, before any resulting product revenue. The company said the arrangement will be funded from operating cash flow, requires no new financing and leaves its full-year 2026 guidance unchanged.
Initial focus on cancer and thyroid eye disease
Initial development is expected to focus on polatuzumab vedotin, an antibody-drug conjugate used to treat diffuse large B-cell lymphoma, and teprotumumab, a monoclonal antibody used for thyroid eye disease. Fresenius said the prospective portfolio spans 13 therapeutic areas, adding opportunities in neurology, nephrology and cardiopulmonary disease alongside its existing positions in oncology, immunology and gastroenterology.
The technologies covered include monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. WuXi Biologics would provide development capabilities through its global network. Fresenius will determine the long-term manufacturing strategy for each candidate, with the option to transfer selected products to its mAbxience network, which became wholly owned in October.
“We are doubling down on our Biopharma business,” Fresenius Chief Executive Michael Sen said in the announcement. He described the agreement as a way to gain development capacity while retaining economic ownership, strategic control and flexibility over capital allocation.
The agreement adds potential growth beyond the company’s existing 2030 Biopharma targets. Those targets, which remain unchanged, call for approximately doubling revenue from 2025 at an operating profit margin of around 20% and relate to the existing marketed and late-stage portfolio.
Access to candidates does not mean new medicines are approved or certain to launch. Fresenius cautioned that whether, when and how many candidates proceed depends on future option decisions, and that there is no assurance any or all will be developed or reach the market.
JBizNews Desk | New York
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
